INSYS Therapeutics, Inc. announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the company's Board of Directors to resign as President and CEO of the company. In connection with company's leadership changes, Andrece Housley, company's Corporate Controller, has been appointed Chief Financial Officer, succeeding Mr. Long.

Additionally, Dr. Venkat Goskonda has been promoted to Chief Scientific Officer, overseeing the company's R&D and manufacturing activities. Mr. Long joined INSYS as Chief Financial Officer in August 2017 with more than three decades of experience in the life sciences, bio-pharma and industrial sectors. Prior to joining INSYS, he served as Senior Vice President of Global Finance at Patheon, where he worked on a number of initiatives leading up to Patheon's IPO.

Prior to working at Patheon, Mr. Long spent nine years as Vice President of Finance for multiple divisions at Thermo Fisher Scientific.